For Immediate Release  

MD Rocky View, Alberta, May 24, 2018 – Sundial Growers Inc. (“Sundial”) (the “Company”) has signed a letter of intent for the supply of 99.5% CBD isolate from Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (“Isodiol”). The supply agreement gives Sundial access to quality pharmaceutical and nutraceutical grade CBD isolate.

“We continue to see a strong demand in Canada for CBD products and we are pleased to add another key supply agreement with a leading pharmaceutical grade consumer product manufacturer” said Sundial CEO, Torsten Kuenzlen. “We look forward to formulating additional products with both pharmaceutical and nutraceutical grade CBD isolate provided by Isodiol.”

Isodiol is a global innovator that specializes in the development of pharmaceutical and wellness products, which recently announced that its wholly owned subsidiary BSPG Laboratories Ltd. has received government approval for the manufacturing of the active substance cannabidiol (CBD) in the United Kingdom.

“Isodiol continues to position itself as a go-to partner in the global supply for the highest quality, pharmaceutical grade CBD isolate,” said Isodiol CEO, Marcos Agramont. “We are pleased to begin this new relationship with Sundial and to assist them in producing products their customers can trust.”

Under the terms of the agreement, CBD will be imported into Canada through a Health Canada approved Licensed Dealer. All imported products will be tested by Sundial in accordance with Canadian standards. Sundial and Isodiol intend to execute a Definitive Supply Agreement which will be subject to required regulatory approvals, including those from applicable exchanges and government authorities in the United Kingdom and Canada and receipt of all related permits.